Gabapentin enacarbil

Drug Profile

Gabapentin enacarbil

Alternative Names: 1838262; ASP8825; Gabapentin-XP; GSK 1838262; Horizant; Regnite; Solzira; XP13512

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XenoPort
  • Developer Arbor Pharmaceuticals; Astellas Pharma; GlaxoSmithKline; National Institute on Alcohol Abuse and Alcoholism; XenoPort
  • Class Acetic acids; Antiepileptic drugs; Carbamates; Cyclohexanecarboxylic acids; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Restless legs syndrome

Highest Development Phases

  • Marketed Postherpetic neuralgia; Restless legs syndrome
  • Phase II Alcoholism
  • Discontinued Diabetic neuropathies; Migraine

Most Recent Events

  • 19 Jul 2017 XenoPort terminates a phase I trial in Restless legs syndrome (In adolescents) in USA, due to lack of enrolment (PO) (NCT02633657)
  • 01 Mar 2017 XenoPort completes the phase II trial in Alcoholism in USA (PO) (NCT02252536)
  • 22 Jan 2016 Phase-I clinical trials in Restless legs syndrome (In adolescents) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top